Julie Hill

EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial

Andrew S.C. Rice, Robert H. Dworkin, Tom D. McCarthy et al. · The Lancet · 2014 · 200 citations

Medicine, Neurology, Pharmacotherapy +8

A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson's disease left untreated at diagnosis

Donald G. Grosset, L Taurah, David J. Burn et al. · Journal of Neurology Neurosurgery & Psychiatry · 2006 · 180 citations · Full text

Pharmacy, Neurology, Behavioral Health +16

Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study

Priscilla Hollander, Jie Liu, Julie Hill et al. · Diabetes Therapy · 2017 · 108 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin

Priscilla Hollander, Julie Hill, Jeremy Johnson et al. · Current Medical Research and Opinion · 2019 · 50 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo‐controlled 54‐week trial in patients with type 2 diabetes (一项为期54周的对持续使用二甲双胍与罗格列酮联合治疗的2型糖尿病患者加用西格列汀治疗的有效性与安全性的随机安慰剂对照研究)*

Adrian S. Dobs, Barry J. Goldstein, Pablo Aschner et al. · Journal of Diabetes · 2012 · 41 citations

Medicine, Pharmacology, Pharmacotherapy +16